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Aim To investigate the efficacy of adalimumab treatment 
in an experimental rat sclerosing encapsulated peritonitis 
(SEP) model.
Methods The study involved 40 Wistar albino rats divid-
ed into four groups: chlorhexidine (CH) group, control 
group, CH + adalimumab group, and CH + resting group. 
The control group received normal saline intraperitoneally 
(i.p.). Other groups received 0.1% CH gluconate, 15% etha-
nol, and normal saline mixture i.p. for three weeks in order 
to induce SEP. CH + adalimumab group received 5 mg/kg 
adalimumab i.p. at the beginning of week 4 and week 6, 
while CH + resting group was followed-up for three weeks 
without applying any procedure after the onset of SEP. Rats 
in groups CH and control group were sacrificed on day 21, 
and rats in group CH + adalimumab and CH + resting were 
sacrificed on day 42. All groups were evaluated for perito-
neal thickness, inflammation, vascularization, and fibrosis.
Results CH + adalimumab group showed a significant de-
crease in peritoneal thickness, fibrosis score, and vascular 
score compared with CH group and CH + resting group.
Conclusion Adalimumab can prevent SEP development.
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Sclerosing encapsulated peritonitis (SEP) is a rare com-
plication of peritoneal dialysis, with high morbidity and 
mortality. The pathological findings of SEP include me-
sothelial denudation, increase in submesothelial thick-
ness, interstitial fibrosis, and vasculopathy (1). Although 
currently there is no effective treatment for SEP, the dis-
continuation of peritoneal dialysis, corticosteroid and 
tamoxifen use, surgical treatments, and total parenteral 
nutrition can be applied (2). Therapies targeting vascu-
lar endothelial growth factor (VEGF), renin-angiotensin 
aldosterone system, or erythropoietin and immunosup-
pressive drugs have been tested in experimental perito-
neal sclerosis models. Some of these therapies positively 
affected peritoneal thickness, vascularization, and fibrosis 
(3-7), whereas others produced no response or produced 
negative results (8,9).
A central role in the pathophysiology of SEP is played by 
transforming growth factor beta (TGF-β) (10), whose pro-
duction is triggered by transmembrane TNF-α reverse sig-
nal in macrophages (11). This is why we hypothesized that 
adalimumab, as a monoclonal antibody against tumor ne-
crosis factor-alpha (TNF-α) (12), could prevent SEP devel-
opment. Adalimumab therapy has previously been shown 
to revert angiogenesis in patients with psoriasis (13), while 
anti-TNF therapy has led to clinical and endoscopic recov-
ery in Crohn’s disease, both by inhibiting vascular prolifera-
tion and due to its anti-inflammatory effects (14). The aim 
of our study was to investigate the efficacy of adalimumab 
therapy in an experimental rat SEP model.
MATERIAL AND METHODS
Experimental animals
The study was performed in Canakkale Onsekiz Mart Uni-
versity Experimental Research Application and Research 
Center Laboratory between June and September 2016. It 
involved forty 6-8-month-old Wistar albino rats (20 males 
and 20 females) weighing between 200 and 250 g. The 
rats were kept in cages containing five rats under stan-
dard caging conditions at 24°C room temperature with 12 
hours of dark/light cycle and standard feeding and water 
supply. At the end of the study, pain control was achieved 
before anesthesia by 5 mg/kg intramuscular (i.m.) lido-
caine injection. Rats were then sacrificed by using 60 mg/
kg i.m. ketamine hydrochloride injection on day 21 or on 
day 42, depending on the group. The rats with signs of 
infection and systemic reaction to adalimumab were 
excluded from study.
The study was approved by Canakkale Onsekiz Mart Uni-
versity animal ethics committee (Decision No:2016/01-03, 
Approval date: January 21, 2016).
Experimental design
Experimental SEP was induced according to Ishii et al (15). 
A mixture of 0.1% chlorhexidine (CH) gluconate (Drogsan 
Medicines Inc. Balgat, Ankara), 15% ethanol, and normal sa-
line (NS) (10 mL/kg/d) was prepared and used aseptically. 
Adalimumab (Humira, 40 mg/0.8 mL [AbbVie, North Chica-
go, IL, USA]) was injected intraperitoneally (i.p.) at a dose of 
5 mg/kg after having been dissolved in 40 mL of NS (1 mg/
mL) (16). To eliminate the effects of direct damage to the 
peritoneum by repeated injections, daily injections were 
performed on the lower quadrant of the abdomen with 
a 21-G needle, and parietal peritoneum in the upper left 
quadrant was used for pathological examinations.
Four groups were formed with 10 rats in each. The duration 
of the study was 21 days for CH and control groups and 42 
days for other groups. The groups were the following:
1. CH group (group 1) received a mixture of 0.1% CH glu-
conate, 15% ethanol, and NS (10 mL/kg/d) i.p. every day.
2. Control group (group 2) received NS (10 mL/kg/d) i.p. 
every day.
3. CH + adalimumab group (group 3) received a mixture of 
0.1% CH gluconate, 15% ethanol, and NS (10 mL/kg/d) i.p. 
every day for 21 days. Adalimumab was administered bi-
weekly at the fourth and sixth week at a dose of 5 mg/kg.
4. CH + resting group (group 4) received a mixture of 0.1% 
chlorhexidine gluconate, 15% ethanol, and NS (10 mL/
kg/d) i.p. every day for 21 days. During the following 21 
days, no intervention was performed.
Histopathological evaluation
All of the formaldehyde fixed parietal peritoneal tissue 
samples were embedded vertically in paraffin after rou-
tine tissue follow-up, and 5-mm thick sections were made. 
The sections were stained with hematoxylin and eosin 
(H&E) and Masson’s trichrome (MT) dyes. The stained 
sections were evaluated under light microscopy for pa-
rietal peritoneal thickness, inflammation, and fibrosis. In 
addition, 4-μm sections were prepared from all samples 
on negatively charged slides, and immunohistochemi-
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cal analyses were performed with use of TGF-β1 (1/100, 
mouse monoclonal immunoglobulin G [IgG], Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA), VEGF (1/100, rabbit 
polyclonal IgG, Spring Bioscience, Pleasanton, CA, USA), 
and alpha-smooth muscle actin (α-SMA, 1/100, mouse 
monoclonal IgG, Cell Marque, Rocklin, CA, USA) antibod-
ies. All pathological examinations were performed by a 
single pathologist who was blinded to the characteristics 
of the groups.
To measure parietal peritoneal thickness, microscopic 
images obtained from H&E-stained sections were trans-
ferred to a computer using Nikon software, version 4.30 
(Nikon Instruments Inc., New York, NY, USA). Parietal peri-
toneal thickness was measured at ten regions in microm-
eters, and mean thickness was recorded. Inflammation 
and fibrosis were semiquantitatively scored using H&E 
stain and MT stain, respectively (15). Inflammation score 
was classified as: 0 – no inflammation or the presence of 
isolated inflammatory cells; 1 – mild inflammation: the 
presence of a few scattered inflammatory cells; 2 – mod-
erate inflammation: the presence of large numbers of in-
flammatory cells in small groups within one high mag-
nification area; 3 – severe inflammation: the presence of 
inflammatory cells with a diffuse distribution or in large 
groups. Fibrosis score was classified as: 0 – no fibrosis; 1 
– mild; 2 – moderate; 3 – severe fibrosis. Vascular score 
was obtained by counting vascular structures reacting 
to α-SMA immunohistochemical staining with use of 
200 × magnification at ten regions for each section, and 
calculating their average (5).
TGF-β1 and VEGF score was obtained by counting fibro-
blast and macrophage cells reacting to TGF-β1 and VEGF 
immunohistochemical staining with use of 200 × magnifi-
cation at ten regions for each section, and calculating their 
average (5). Vasculopathy was graded according to the de-
gree of subendothelial hyalinization, luminal irregularity, 
and narrowing, as described by Williams et al (17).
Statistical analysis
All results are expressed as median (Q1-Q3). Due to the lim-
ited number of rats in each group, non-parametric meth-
ods were used. The difference in the distribution of categor-
ical data was analyzed with the χ2 test. Peritoneal thickness, 
inflammation, fibrosis, and vascular score; and VEGF and 
TGF-β1 scores were compared between the groups with 
the Kruskal-Wallis test. In the post-hoc analysis, the Mann-
Whitney U test with Bonferroni correction was used. Statis-
tical significance level was P < 0.008 for the Mann-Whitney 
U test with Bonferroni correction and P < 0.05 for the other 
tests. The analyses were performed using the SPSS, version 
20.0 for Windows (IBM Corp, Armonk, NY, USA).
RESULTS
All 40 rats completed the study. CH group showed thicken-
ing in the parietal peritoneum and adhesion in the abdom-
inal wall during scarification, while these changes were ab-
sent in the control group. Control group had significantly 
lower median peritoneal thickness than CH group, CH + 
resting group, and CH + adalimumab group, (P = 0.0001, 
P = 0.0001, and P = 0.003, respectively). CH + adalimumab 
group had significantly lower median peritoneal thickness 
than CH group and CH + resting group (P = 0.0001 and 
P = 0.0001, respectively) (Table 1 and Figure 1).
Control group had significantly lower median inflamma-
tion score than CH group, CH + resting group, and CH + 
adalimumab group (P = 0.0001, P = 0.0001, and P = 0.002, 
respectively). CH + adalimumab group had significantly 
lower median inflammation score than CH + resting group 
(P = 0.005).
Control group had significantly lower median fibrosis score 
than CH group, CH + resting group, and CH + adalimum-
ab group (P = 0.0001, P = 0.0001, and P = 0.001, respective-
ly). CH + adalimumab group had significantly lower me-
TABLE 1. Peritoneal thickness, inflammation, fibrosis, vascular score, vascular endothelial growth factor (VEGF), and transforming 
growth factor beta (TGF-β1) scores in different study groups
Variables, median (Q1-Q3)
Chlorhexidine 
group (n = 10)
Control 
group (n = 10)
Chlorhexidine + adalimumab
group (n = 10)
Chlorhexidine + resting 
group (n = 10) P*
Peritoneal thickness (μm) 394.4 (323.1-454.7) 82.8 (66.9-121.9) 181.7 (130.2-201.1) 539.8 (381.6-649.5) 0.0001
Inflammation score   1.0 (1-1)  0.0 (0-0)   1.0 (0-1)   1.5 (1-2) 0.0001
Fibrosis score   2.0 (1-2)  0.0 (0-0.5)   1.0 (1-1)   2.0 (2-3) 0.0001
Vascular score   8.0 (7-9)  0.0 (0-0)   5.0 (4.75-6)  14.8 (15-16.3) 0.0001
VEGF   5.0 (4.8-6)  0.0 (0-0)   3.0 (3-4)   7.0 (6.75-8.25) 0.0001
TGF-β1   2.0 (1.8-2)  0.0 (0-0)   1.0 (0-1)   2.0 (1.8-3) 0.0001
*Kruskal-Wallis test.
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dian fibrosis score than CH group and CH + resting group 
(P = 0.007 and P = 0.001, respectively).
Control group had significantly lower median vascular 
score than CH group, CH + resting group, and CH + adali-
mumab group (P = 0.0001, P = 0.0001, and P = 0.0001, re-
spectively). CH + adalimumab group had significantly low-
er median vascular score than CH group and CH + resting 
group (P = 0.001, P = 0.0001, respectively).
Control group had significantly lower mean VEGF score than 
CH group, CH + resting group, and CH + adalimumab group 
(P = 0.0001, P = 0.0001, and P = 0.0001, respectively). CH + 
adalimumab group had significantly lower median VEGF 
score than CH group and CH + resting group (P = 0.0001). 
Parietal peritoneal images obtained by using VEGF immu-
nohistochemical staining are shown in Figure 2.
Control group had significantly lower median TGF-β1 than 
CH group, CH + resting group, and CH + adalimumab 
group (P = 0.0001, P = 0.0001, and P = 0.002, respectively). 
CH + adalimumab group had significantly lower medi-
an TGF-β1 score than CH group and CH + resting group 
(P = 0.0001 and P = 0.001, respectively). Parietal peritoneal 
images obtained by TGF-β1 immunohistochemical stain-
ing are shown in Figure 3.
DISCUSSION
Our study found that adalimumab prevented the develop-
ment of experimental SEP. Although our experimental SEP 
model was created according to Ishii et al (15), we studied 
the development of peritoneal fibrosis for 3 rather than for 
8 weeks. In our study, CH group had significantly higher 
parietal peritoneal thickness, inflammation, and fibrosis 
scores compared with the control group, indicating that 
peritoneal fibrosis was effectively induced. In CH + rest-
ing group, morphological peritoneum changes were not 
reversed and they even progressed, suggesting that the 
peritoneum was still active.
FIGURE 1. Histopathological images of the parietal peritoneum thickness (hematoxylin and eosin ×10). (A) Control group; (B) Chlor-
hexidine group; (C) Chlorhexidine + resting group; (D) Chlorhexidine + adalimumab group.
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In experimental SEP models, some therapies (VEGF inhibi-
tor, renin-angiotensin system inhibitors, aliskiren, erythro-
poietin, and thalidomide) reduced peritoneal thickness, 
vascularization, and fibrosis (3-7). However, some therapies 
(calcium channel blocker and cyclosporine) yielded no 
positive results and may even pose a risk for the develop-
ment of SEP (8,9).
TNF-α acts on innate immune cells and contributes to the 
development of fibrosis (18). However, it also suppresses fi-
brosis by down-regulating connective tissue growth factor 
(CTGF) in fibroblasts (19). In our study, the first to use adali-
mumab in an experimental SEP model, CH + adalimumab 
treated animals had significantly lower peritoneal thick-
ness, inflammation, fibrosis, and vascular score compared 
with CH group and CH + resting group.
Factors that contribute to the pathogenesis of SEP are VEGF 
and TGF-β (10). Human peritoneal mesothelial cells play an 
important role in VEGF synthesis, and VEGF release increas-
es in the presence of proinflammatory cytokines. VEGF can 
increase vascular permeability, vasodilatation, and neoan-
giogenesis in the peritoneal membrane (20). Some thera-
pies (aliskiren, erythropoietin, and thalidomide) applied af-
ter inducing an experimental SEP model decreased TGF-β 
and VEGF release (5-7). In our study, CH + adalimumab sig-
nificantly decreased TGF-β1 and VEGF compared with CH 
and CH + resting groups, probably because of anti-TNF ef-
fects of adalimumab. Anti-inflammatory and angiogenic 
activity of TNF-α inhibitors has been demonstrated in the 
treatment of immune-associated diseases. In addition, an-
giogenic effects of TNF are due to changed expression of 
VEGF and its endothelial receptor VEGF receptor 2 (21).
Other substances that play a role in the pathogenesis of 
SEP are fibroblast growth factor (FGF), matrix metallopro-
teinase (MMP), and myeloperoxidase (10). Serum FGF and 
VEGF levels in psoriatic patients were decreased by anti-
TNF therapy (infliximab) (22). MMP-3 was significantly re-
duced by the addition of adalimumab therapy in patients 
with rheumatoid arthritis (23) and by TNF-α antagonist 
therapy (infliximab, etanercept, and adalimumab) in pa-
FIGURE 2. Parietal peritoneal images obtained by using vascular endothelial growth factor immunohistochemical staining. (A) Control 
group ( × 10); (B) Chlorhexidine group ( × 10); (C) Chlorhexidine + resting group ( × 10); (D) Chlorhexidine + adalimumab group ( × 20).
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tients with spondyloarthritis (24,25). Adalimumab therapy 
also reduced myeloperoxidase activity (26,27). TNF-α inhib-
itors suppress nuclear factor-kappaB (NF-кB) activity (28), 
but one study showed that adalimumab therapy was not 
effective on the NF-кB activity of lymphocytes in patients 
with rheumatoid arthritis (29).
A limitation of our study is the fact that it did not investi-
gate immunohistochemical localization of TNF-α and CTGF 
in peritoneal tissue, serum FGF and MMP-3 levels, and my-
eloperoxidase and NF-кB activities. In addition, it did not 
involve groups treated with different adalimumab doses.
In conclusion, this experimental SEP model indicates that 
adalimumab can prevent experimental SEP development. 
However, more extensive experimental and clinical stud-
ies are needed to find the optimal dose and duration of 
treatment.
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